IN PREVIOUSLY UNTREATED METASTATIC OR UNRESECTABLE STAGE III OR IV MELANOMA
RELATIVITY-047: A randomized phase II/III double-blinded trial1,3
RELATIVITY-047 Study Design
Treatment was discontinued in the event of disease progression, unacceptable AEs, or withdrawal of consent.3
AE: adverse event; BICR: Blinded Independent Central Review; ECOG: Eastern Cooperative Oncology Group; IV: intravenous; ORR: objective response rate; OS: overall survival;
PFS: progression-free survival; Q4W: every 4 weeks; RECIST: response evaluation criteria in solid tumors.
* PD-L1 (≥1% vs. <1%) was determined using PD-L1 IHC 28-8 pharmDx test.
† LAG-3 expression (≥1% vs. <1%) as determined by an analytically validated LAG-3 IHC clinical trial assay.
‡ BRAF V600 mutation status (V600 mutation positive vs. wild type).
§ American Joint Committee on Cancer version 8 staging system (M0/M1 any [0] vs. M1 any [1]).
¶ Determined by BICR using RECIST v1.1.